Hypophosphatemia Management

Classification and Diagnosis

Severe hypophosphatemia is defined as a serum phosphate level less than 1.0 mg/dL, which is potentially life-threatening, according to the American Journal of Hematology 1, 2

For X-linked hypophosphatemia (XLH), the recommended oral phosphate supplementation dose is 20-60 mg/kg body weight daily of elemental phosphorus in children, as suggested by Nature Reviews Nephrology 4, 5
The frequency of oral phosphate supplementation can be reduced to 3-4 times daily when alkaline phosphatase normalizes, according to Nature Reviews Nephrology 4, 6
The maximum dose of oral phosphate supplements should be less than 80 mg/kg daily to prevent gastrointestinal discomfort and hyperparathyroidism, as recommended by Nature Reviews Nephrology 4, 3

To manage secondary hyperparathyroidism, the dose of active vitamin D should be increased and/or the dose of oral phosphate supplements decreased, as suggested by Nature Reviews Nephrology 4, 3
Calcimimetics may be considered for persistent secondary hyperparathyroidism, but their use should be cautious due to the risk of hypocalcemia and increased QT interval, according to Nature Reviews Nephrology 5
Parathyroidectomy may be considered for tertiary hyperparathyroidism, as recommended by Nature Reviews Nephrology 5, 3

For children, serum phosphate levels should be monitored every 3 months during rapid growth phases or after therapy initiation, as suggested by Nature Reviews Nephrology 8
For stable patients, serum phosphate levels should be monitored every 6 months, according to Nature Reviews Nephrology 8
When using burosumab for XLH, fasting serum phosphate levels should be monitored during the titration period, 7-11 days after injection, as recommended by Nature Reviews Nephrology 6, 9

Inadequate frequency of oral phosphate supplementation can lead to treatment failure, as noted by Nature Reviews Nephrology 4, 6
Not monitoring for secondary hyperparathyroidism during phosphate supplementation can lead to complications, according to Nature Reviews Nephrology 4, 3
Missing treatment-emergent hypophosphatemia after IV iron administration can lead to severe consequences, as warned by the American Journal of Hematology 1, 2